HUMABODY
LIVE

Serial Number

79179556

Owner

Crescendo Biologics Limited

Attorney

Rebecca Liebowitz

Filing Date

Dec 17, 2014

Add to watchlist:

No watchlists yet
View on USPTO

HUMABODY Trademark

Serial Number: 79179556 • Registration: 5158366

HUMABODY is a trademark filed by Crescendo Biologics Limited on December 17, 2014. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Crescendo Biologics Limited (6 trademarks)

Meditrina Building,

Entity Type: 99

Trademark Details

Filing Date

December 17, 2014

Registration Date

March 14, 2017

Published for Opposition

September 20, 2016

Goods & Services

[ Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments ]

pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; veterinary preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; antibody fragments being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases] ; antibody therapeutics in the nature of therapeutic agents for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; medical diagnostic reagents and veterinary diagnostic reagents in the nature of antibodies and antibody fragments; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] and or use in the manufacture of therapeutic products

chemicals used in industry and science; [ chemical test kits for in vitro testing for laboratory research purposes; ] biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments for in vitro scientific and laboratory research use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products

[ Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; Scientific laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, drug discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design ]

Filing History

PARTIAL INVALIDATION PROCESSED BY THE IB
Jun 20, 2025 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
May 12, 2025 INPS
INVALIDATION PROCESSED
May 12, 2025 INPC
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
May 12, 2025 LIMN
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Feb 27, 2025 INPR
INTERNATIONAL REGISTRATION RENEWED
Dec 12, 2024 RNWL
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Nov 8, 2024 RHRD
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Jun 27, 2024 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
Jun 27, 2024 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 7, 2024 APRE
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 27, 2023 LIMN
TEAS SECTION 71 RECEIVED
Sep 13, 2023 ES71
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Aug 19, 2023 RHRD
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 14, 2022 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Dec 7, 2017 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 14, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 22, 2017 FICS
FINAL DISPOSITION PROCESSED
Jun 22, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 14, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 14, 2017 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Feb 3, 2017 ETOP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 18, 2016 OPNX
EXTENSION OF TIME TO OPPOSE RECEIVED
Oct 18, 2016 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 20, 2016 NPUB
PUBLISHED FOR OPPOSITION
Sep 20, 2016 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 31, 2016 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 31, 2016 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 31, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 17, 2016 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 9, 2016 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 9, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 9, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 9, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 9, 2016 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 8, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 8, 2016 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 8, 2016 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 29, 2016 GNFN
FINAL REFUSAL E-MAILED
Jul 29, 2016 GNFR
FINAL REFUSAL WRITTEN
Jul 29, 2016 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 15, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 15, 2016 CRFA
ASSIGNED TO LIE
Jul 15, 2016 ALIE
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 11, 2016 TCCA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 11, 2016 TROA
REFUSAL PROCESSED BY IB
Feb 1, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 11, 2016 RFCS
REFUSAL PROCESSED BY MPU
Jan 11, 2016 RFRR
APPLICATION FILING RECEIPT MAILED
Jan 8, 2016 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 6, 2016 RFCR
NON-FINAL ACTION WRITTEN
Jan 5, 2016 CNRT
ASSIGNED TO EXAMINER
Jan 4, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 4, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 3, 2016 REPR